Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 221

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 19
Chunk 221
---
IES

Notes to Consolidated Financial Statements

1. Reporting Entity

Takeda Pharmaceutical Company Limited (the “ Company”) is a public company incorporated in Japan. The Company and its subsidiaries (collectively, “ Takeda”) is a global, values-based, R& D-driven biopharmaceutical company with a diverse portfolio, engaged primarily in the research, development, production and global commercialization of pharmaceutical products. Takeda’s principal pharmaceutical products include medicines in the following key business areas: Gastroenterology (“ GI”), Rare Diseases, Plasma-Derived Therapies (“ PDT”), Oncology, Vaccines and Neuroscience.

2. Basis of Preparation

Compliance with International Financial Reporting Standards

Takeda’s consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“ IFRS”), as issued by the International Accounting Standards Board (“ IASB”). The term IFRS also includes International Accounting Standards (“ IASs”) and the related interpretations of the interpretation’s committees (Standard Interpretations Committee (“ SIC”) and International Financial Reporting Interpretations Committee (“ IFRIC”)).

Approval of Financial Statements

The Company’s consolidated financial statements presented were approved on June 25, 2025 by Representative Director, President & Chief Executive Officer (“ CEO”) Christophe Weber and Director & Chief Financial Officer (“ CFO”) Milano Furuta.

Basis of Measurement

The consolidated financial statements have been prepared on a historical cost basis, except for certain assets and liabilities recorded at fair value including equity investments, derivative financial instruments, financial assets and liabilities associated with contingent consideration arrangements, and the application of hyperinflationary accounting at subsidiaries.

Functional and Presentation Currency

The consolidated financial statements are presented in Japanese Yen (“ JPY”), which is the functional currency of the Company. All financial information presented in JPY has been rounded to the nearest million JPY, except when otherwise indicated. In tables with rounded figures, sums may not add up due to rounding.

New Accounting Standards and Interpretations Adopted

During the year ended March 31, 2025, there were no new accounting standards applied by Takeda that had a significant impact on Takeda’s consolidated financial statements.

New Accounting Standards and Interpretations Issued and Not Yet Adopted

On April 9, 2024, the IASB has issued IFRS 18 Presentation and Disclosure in Financial Statements(“ IFRS 18”), which replaces IAS 1 Presentation of Financial Statements.

IFRS 18 introduces certain new requirements to